Ihde D C
Cancer. 1984 Dec 1;54(11 Suppl):2722-8. doi: 10.1002/1097-0142(19841201)54:2+<2722::aid-cncr2820541419>3.0.co;2-p.
Small cell carcinoma of the lung (SCCL) is distinguished from other types of lung cancer by its propensity for early development of distant metastases and its rapidly fatal clinical course in the absence of treatment. The introduction of chemotherapy into the management of SCCL has led to a four- to five-fold improvement in median survival and to the cure of a small proportion of patients with this disease. Employment of three- or four-drug regimens with or without chest irradiation in moderately intensive doses for periods of 12 months or less has proven to be the optimal therapeutic strategy with currently available agents. Despite these substantial gains, it is obvious that the vast majority of SCCL patients are continuing to die from their cancer, and a slowing in the pace of treatment advances has become apparent over the past 5 years. This article reviews current areas of active clinical investigation in SCCL and some information developed in the cell biology laboratory that may have eventual application in the clinic.
肺小细胞癌（SCCL）与其他类型肺癌的区别在于其早期易发生远处转移的倾向，以及在未接受治疗时迅速致命的临床病程。化疗引入SCCL的治疗后，患者的中位生存期提高了四至五倍，一小部分患者得以治愈。采用三药或四药方案，联合或不联合中等强度胸部照射，疗程为12个月或更短时间，已被证明是目前可用药物的最佳治疗策略。尽管取得了这些显著进展，但显然绝大多数SCCL患者仍死于癌症，而且在过去5年中，治疗进展的速度明显放缓。本文综述了SCCL目前活跃的临床研究领域，以及细胞生物学实验室所取得的一些可能最终应用于临床的信息。
